Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BPX-601 + Rimiducid |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BPX-601 | GoCART BPX-601|iMC/PSCA-zeta BPX 601|Autologous PSCA CAR T Cells BPX-601 | PSCA Immune Cell Therapy 3 | BPX-601 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting human prostate stem cell antigen (PSCA) and the zeta chain of the T-cell receptor (TCRzeta), and a rimiducid-induced co-stimulatory molecule, which activates anti-tumor immune response (PMID: 27824842). | |
| Rimiducid | AP1903|AP-1903|AP 1903 | Rimiducid (AP1903) is a small molecule that selectively binds to mutant FKBP12 and induces dimerization and downstream signaling, which can be used to activate a safety switch in transplanted cells to potentially induce apoptosis and prevent graft-versus-host disease (PMID: 9724721, PMID: 22047558, PMID: 28697888). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02744287 | Phase Ib/II | BPX-601 + Rimiducid | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors | Suspended | USA | 0 |